(Q43624352)

25 November 2017

title

Is infliximab effective for induction of remission in patients with ulcerative colitis? (English)

1 reference

25 November 2017

Lichtenstein GR

1

1 reference

25 November 2017

publication date

1 May 2001

1 reference

Inflammatory Bowel Diseases

25 November 2017

published in

1 reference

25 November 2017

volume

7

1 reference

25 November 2017

issue

2

1 reference

25 November 2017

page(s)

89-93

1 reference

Medical therapy for Crohn's disease: the state of the art.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Novel therapies for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Tumor necrosis factor alpha regulates proliferation in a mouse intestinal cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of a human salivary gland cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Synergistic effects of interferon gamma and tumour necrosis factor alpha on T84 cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200105000-00002

10.1097/00054725-200105000-00002

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference